This Duke Consortia for HIV/AIDS Vaccine Development (CHAVD) funded in 2019 will apply state-of-the-art technologies and immunologic tools to focus on iterative, rational vaccine design that within 7 years will lead to a successful final vaccine design. There were two consortiums funded, one at Duke University and one at Scripps Research Institute.